ReviewBME frontiers2026
De Novo Design Strategies of Nanomedicines for Diabetic Wound Microenvironment Remodeling.
Review in BME frontiers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds are arrested by a hostile microenvironment of hyperglycemia, inflammation, infection, and hypoxia. Nanomaterials offer solutions, yet existing reviews lack a systematic framework linking their actions to the interconnected pathological network. Here, we present a pathology network-guided analysis. We delineate how engineered nanosystems from metal-based antimicrobials to glucose-responsive nanoreactors and extracellular vesicles can intercept multiple drivers, including advanced glycation end-products, oxidative stress, biofilms, and immune dysregulation. Critically, we propose a temporally phased roadmap that prioritizes neutralization of upstream drivers (hyperglycemia and biofilms) before downstream interventions (reactive oxygen species scavenging, immunomodulation, and angiogenesis), avoiding premature single-target therapy. Beyond efficacy, we critically address design trade-offs: we examine the evidence for metal nanomaterial selectivity toward bacteria versus stressed host cells, confront bacterial adaptive resistance (efflux pumps and biofilm reinforcement), and scrutinize the trade-off, manufacturing scalability, long-term biosafety, and regulatory ambiguities. By integrating mechanistic insights with clinical scalability and regulatory feasibility, we provide a conceptual framework to guide the rational design of next-generation nanomedicines that prioritize genuine synergy over redundant integration, and outline a roadmap for translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.